Fibrin degradation products: A review of structures found in vitro and in vivo

Annals of the New York Academy of Sciences

Volumn 936, Issue , 2001, Pages 594-610

  Gaffney, Patrick J ^a,b  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Fibrin degradation products; Structures in vitro; Structures in vivo

Indexed keywords

ANTIFIBRINOLYTIC AGENT; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOPEPTIDE A; PLASMIN;

ALPHA CHAIN; BLOOD CLOTTING; BLOOD SAMPLING; BLOOD VESSEL REACTIVITY; CARBOXY TERMINAL SEQUENCE; CONFERENCE PAPER; DISEASE MARKER; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRIN FORMATION; FIBRIN POLYMERIZATION; FIBRINOGEN SYNTHESIS; FIBRINOGENOLYSIS; FIBRINOLYSIS; HUMAN; PROTEIN CROSS LINKING; PROTEIN DOMAIN;

EID: 0034952378     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03547.x     Document Type: Conference Paper

References (69)

1. The biochemistry of fibrinogen and fibrin degradation products
2. Structure of fibrinogen and degradation products on fibrinogen and fibrin
3. A molecular model of plasmic degradation of crosslinked fibrin
4. Fibrinolysis
5. On the structure of fibrinogen related to its plasmic degradation products D and E
6. D dimer. History of the discovery, characterisation and utility of this and other fibrin fragments
7. Molecular mechanisms of physiological fibrinolysis
8. On the regulation and control of fibrinolysis
9. Molecular mechanisms of thrombolysis. Implications for therapy
10. Exercise-induced fibrinolysis - Fact or fiction?
11. Decomposition products of fibrinogen and fibrin
12. Les produits de degradation du fibrinogene humain par la plasmine, I: Separation et proprietes physicochemiques
13. High molecular weight derivatives of human fibrinogen produced by plasmin. I: Physiochemical and immunological characterization
14. High molecular weight derivatives of human fibrinogen produced by plasmin
15. The products of the action of thrombin on fibrinogen
16. N-terminal disulphide knot of human fibrinogen
17. On the structure of the COOH-terminal part of the alpha chain of human fibrinogen
18. A structural aspect of human fibrinogen suggested by its plasmin degradation
19. Structural aspects of the fibrinogen-fibrin conversion
20. Fibrin: Structure and interactions
21. The essential covalent structure of human fibrinogen evinced by analysis of derivatives formed during plasmic hydrolysis
22. Crosslinking of rabbit fibrin in vivo
23. Fibrin subunits in venous and arterial thromboembolism
24. Evidence for localisation of polymerisation sites in fibrinogen
25. Fate of ribrinopeptides in the reaction between human plasmin and fibrinogen
26. On the significance of the release of two different peptides from fibrinogen during clotting
27. The identification of isopeptide crosslinks in insoluble fibrin
28. Crosslink in fibrin polymerized by factor XIII ε-(γ-glutamyl) lysine
29. Fibrin crosslinks and lysis rates
30. Subunit relationships between fibrinogen and fibrin degradation products
31. Human factor XIII from plasma and platelets. Molecular weights, subunit structure, proteolytic activation and crosslinking of fibrinogen and fibrin
32. The effect of plasmin on the subunit structure of human fibrin
33. Subunit structure of fragment D from ribrinogen and crosslinked fibrin
34. Studies on the "double D" fragment from stabilised bovine fibrin
35. Giant fibrin fragments derived from crosslinked fibrin: Structural and clinical implication
36. Distinction between fibrinogen and fibrin degradation products in plasma
37. Detection and relevance of crosslinked fibrin derivatives in blood
38. Subunit and macromolecular structure of circulating fibrin from obstetric patients with intravascular coagulation
39. The occurrence and clinical relevance of fibrin fragments in blood
40. Soluble high molecular weight E fragments in the plasmin-induced degradation products of cross-linked human fibrin
41. Effects of fibrinopeptide cleavage on the plasmic degradation pathways of human crosslinked fibrin
42. Normal and fibrinaemic patient plasma contain high molecular weight cross-linked fibrin(ogen) derivatives with intact fibrinopeptide A
43. Fibrin degradation products (FnDP) assays. Analysis of standardisation issues and target antigens in plasma
44. A rapid monoclonal antibody-based enzyme immunoassay (EIA) for the quantitative determination of soluble fibrin in plasma
45. A quantitative enzyme immunoassay (EIA) for primary fibrinogenolysis products in plasma
46. The effect of alcohol ingestion on the exercise-induced changes in fibrin and fibrinogen degradation products in man
47. A new enzyme immunoassay for soluble fibrin in plasma, with a high discriminating power for thrombotic disorders
48. Significance of cross-linking of α2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis
49. Soluble fibrin species in arterial thrombi
50. Fibrinolysis and the haemostatic balance: Harmonisation of some old and new concepts
51. The biological significance of fibrinolysis
52. Hypercoagulability and ischaemic heart disease
53. Factors regulatory plasma protein synthesis II: Influence of fibrinogenolytic products on plasma fibrinogen concentration
54. Failure of fibrinogen degradation products to increase plasma fibrinogen in rabbits
55. Effect of fibrin degradation products and thrombin on fibrinogen synthesis
56. Stimulation of fibrinogen synthesis: A possible functional role of fibrinogen degradation products
57. Fibrinogen fragments X,Y,D & E increase levels of plasma fibrinogen and liver mRNAs coding for fibrinogen polypeptides in rats
58. Effect of fibrinogenolytic products D & E on fibrinogen and albumin synthesis in the rat
59. Stimulation of fibrinogen biosynthesis by fibrinogen fragments D & E
60. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: An indirect feedback pathway
61. Stimulation of fibrinogen synthesis in cultured rat hepatolytes by fibrinogen fragment E
62. Stimulation of fibrinogen synthesis in cultured rat hepatocytes by fibrinogen degradation products fragment D
63. Vasoactive peptides derived from degradation of fibrinogen and fibrin
64. Effects of early plasmin digests of fibrinogen on isometric tension development in isolated rings of rat pulmonary artery
65. FDP
66. A reference material for haemonisation of D dimer assays
67. The importance of antibody specificity in measuring crosslinked from degradation products by ELISA
68. Diagnostic value of plasma D dimer in suspected pulmonary embolism
69. Detection of fibrin and its fragments using monoclonal antibodies. Clinical implications